Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Int J Biochem Cell Biol ; 143: 106138, 2022 02.
Artículo en Inglés | MEDLINE | ID: covidwho-1588223

RESUMEN

Nicotinic acetylcholine receptors mediate fast synaptic transmission in neuro-muscular junctions and autonomic ganglia and modulate survival, proliferation and neurotransmitter or cytokine release in the brain and non-excitable cells. The neuronal-type nicotinic acetylcholine receptors are expressed in the outer mitochondria membrane to regulate the release of pro-apoptotic substances like cytochrome c or reactive oxygen species. In the intracellular environment, nicotinic acetylcholine receptor signaling is ion-independent and triggers intramitochondrial kinases, similar to those activated by plasma membrane nicotinic acetylcholine receptors. The present review will describe the data obtained during the last five years including, in particular, post-translational glycosylation as a targeting signal to mitochondria, mechanisms of mitochondrial nicotinic acetylcholine receptor signaling studied with subtype-specific agonists, antagonists, positive allosteric modulators and knockout mice lacking certain nicotinic acetylcholine receptor subunits, interaction of mitochondrial nicotinic acetylcholine receptors with Bcl-2 family proteins and their involvement in important pathologies like neuroinflammation, liver damage and SARS-CoV-2 infection.


Asunto(s)
COVID-19/genética , Enfermedad Hepática Inducida por Sustancias y Drogas/genética , Mitocondrias/genética , Enfermedades Neuroinflamatorias/genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , Receptores Nicotínicos/genética , Regulación Alostérica , Animales , COVID-19/metabolismo , COVID-19/patología , COVID-19/virología , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Modelos Animales de Enfermedad , Humanos , Ratones , Mitocondrias/metabolismo , Enfermedades Neuroinflamatorias/metabolismo , Enfermedades Neuroinflamatorias/patología , Agonistas Nicotínicos/farmacología , Antagonistas Nicotínicos/farmacología , Procesamiento Proteico-Postraduccional , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Receptores Nicotínicos/metabolismo , SARS-CoV-2/patogenicidad , Transducción de Señal , Canal Aniónico 1 Dependiente del Voltaje/genética , Canal Aniónico 1 Dependiente del Voltaje/metabolismo
2.
Front Immunol ; 12: 783725, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1554650

RESUMEN

Interferons (IFNs) are cytokines that possess antiviral, antiproliferative, and immunomodulatory actions. IFN-α and IFN-ß are two major family members of type-I IFNs and are used to treat diseases, including hepatitis and multiple sclerosis. Emerging evidence suggests that type-I IFN receptors (IFNARs) are also expressed by microglia, astrocytes, and neurons in the central and peripheral nervous systems. Apart from canonical transcriptional regulations, IFN-α and IFN-ß can rapidly suppress neuronal activity and synaptic transmission via non-genomic regulation, leading to potent analgesia. IFN-γ is the only member of the type-II IFN family and induces central sensitization and microglia activation in persistent pain. We discuss how type-I and type-II IFNs regulate pain and infection via neuro-immune modulations, with special focus on neuroinflammation and neuro-glial interactions. We also highlight distinct roles of type-I IFNs in the peripheral and central nervous system. Insights into IFN signaling in nociceptors and their distinct actions in physiological vs. pathological and acute vs. chronic conditions will improve our treatments of pain after surgeries, traumas, and infections.


Asunto(s)
Dolor Agudo/inmunología , Dolor Crónico/inmunología , Interferón Tipo I/metabolismo , Interferón gamma/metabolismo , Enfermedades Neuroinflamatorias/inmunología , Dolor Agudo/patología , Animales , Dolor Crónico/patología , Modelos Animales de Enfermedad , Humanos , Neuroglía/citología , Neuroglía/inmunología , Neuroglía/patología , Enfermedades Neuroinflamatorias/patología , Nociceptores/inmunología , Nociceptores/metabolismo , Receptores de Interferón/metabolismo , Transducción de Señal/inmunología , Médula Espinal/citología , Médula Espinal/inmunología , Médula Espinal/patología
3.
Mol Neurobiol ; 59(1): 445-458, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: covidwho-1491383

RESUMEN

In addition to respiratory complications produced by SARS-CoV-2, accumulating evidence suggests that some neurological symptoms are associated with the disease caused by this coronavirus. In this study, we investigated the effects of the SARS-CoV-2 spike protein S1 stimulation on neuroinflammation in BV-2 microglia. Analyses of culture supernatants revealed an increase in the production of TNF-α, IL-6, IL-1ß and iNOS/NO. S1 also increased protein levels of phospho-p65 and phospho-IκBα, as well as enhanced DNA binding and transcriptional activity of NF-κB. These effects of the protein were blocked in the presence of BAY11-7082 (1 µM). Exposure of S1 to BV-2 microglia also increased the protein levels of NLRP3 inflammasome and enhanced caspase-1 activity. Increased protein levels of p38 MAPK was observed in BV-2 microglia stimulated with the spike protein S1 (100 ng/ml), an action that was reduced in the presence of SKF 86,002 (1 µM). Results of immunofluorescence microscopy showed an increase in TLR4 protein expression in S1-stimulated BV-2 microglia. Furthermore, pharmacological inhibition with TAK 242 (1 µM) and transfection with TLR4 small interfering RNA resulted in significant reduction in TNF-α and IL-6 production in S1-stimulated BV-2 microglia. These results have provided the first evidence demonstrating S1-induced neuroinflammation in BV-2 microglia. We propose that induction of neuroinflammation by this protein in the microglia is mediated through activation of NF-κB and p38 MAPK, possibly as a result of TLR4 activation. These results contribute to our understanding of some of the mechanisms involved in CNS pathologies of SARS-CoV-2.


Asunto(s)
Microglía/metabolismo , Enfermedades Neuroinflamatorias/virología , Glicoproteína de la Espiga del Coronavirus/metabolismo , Animales , Caspasa 1/metabolismo , Línea Celular , Furanos/farmacología , Indenos/farmacología , Inflamasomas/metabolismo , Interleucina-1beta/genética , Interleucina-6/metabolismo , Ratones , Microglía/patología , FN-kappa B/metabolismo , Enfermedades Neuroinflamatorias/patología , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Nitrilos/farmacología , ARN Interferente Pequeño , Proteínas Recombinantes/metabolismo , Sulfonamidas/farmacología , Sulfonas/farmacología , Receptor Toll-Like 4/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
4.
Neurochem Int ; 148: 105101, 2021 09.
Artículo en Inglés | MEDLINE | ID: covidwho-1271730

RESUMEN

Central nervous system (CNS) diseases are responsible for a large proportion of morbidity and mortality worldwide. CNS diseases caused by intrinsic and extrinsic stimuli stimulate the resident immune cells including microglia and astrocyte, resulting in neuroinflammation that exacerbates the progression of diseases. Recent evidence reveals the aberrant expression patterns of long non-coding RNAs (lncRNAs) in the damaged tissues following CNS diseases. It was also proposed that lncRNAs possessed immune-modulatory activities by directly or indirectly affecting various effector proteins including transcriptional factor, acetylase, protein kinase, phosphatase, etc. In addition, lncRNAs can form a sophisticated network by interacting with other molecules to regulate the expression or activation of downstream immune response pathways. However, the major roles of lncRNAs in CNS pathophysiologies are still elusive, especially in neuroinflammation. Herein, we tend to review some potential roles of lncRNAs in modulating neuroinflammation based on current evidence in various CNS diseases, in order to provide novel explanations for the initiation and progression of CNS diseases and help to establish therapeutic strategies targeting neuroinflammation.


Asunto(s)
Enfermedades del Sistema Nervioso Central/genética , Enfermedades Neuroinflamatorias/genética , ARN Largo no Codificante/fisiología , Animales , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Enfermedades del Sistema Nervioso Central/patología , Humanos , Enfermedades Neuroinflamatorias/tratamiento farmacológico , Enfermedades Neuroinflamatorias/patología , ARN Largo no Codificante/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA